The progress with small molecule drugs is mirrored by the successful introduction of protein-based therapeutics, particularly antibodies, as exemplified by the anti- ERBB2 monoclonal antibody trastuzumab in ERBB2-positive breast cancer [51, 52]. The gene discussed is ERBB2; the disease is breast carcinoma.